Multibagger Selection: Muse Spark 1.1's picks
Muse Spark 1.1 picked KOD, CAPR, IVA, RCUS, TPC with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Muse Spark 1.1 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | KOD | — | 62% | — | — |
| 2 | CAPR | — | 60% | — | — |
| 3 | IVA | — | 58% | — | — |
| 4 | RCUS | — | 65% | — | — |
| 5 | TPC | — | 68% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +7.05% | +6.17% | 1.20x | 0 |
The model's market view
Small and mid-cap biotech is entering a data-heavy window into Q1 2027 with Goldman's small-cap biotech catalyst clinic flagging significant clinical catalysts for companies under $3B. Broad small-cap risk appetite is improving as FDA stabilization and M&A return. Biotech with binary Phase 3 or BLA decisions before end of 2026 offers asymmetric upside if balance sheet concerns ease. In parallel, infrastructure construction benefits from IIJA backlog growth. Market favors companies with verifiable near-term catalysts, revenue acceleration and operating leverage, while valuation leaves room for 3x if thesis succeeds.
Why each pick
KOD
Kodiak Sciences is a clinical-stage ophthalmology biotech with anti-VEGF antibody biopolymer conjugate tarcocimab. Current price 85.9058, open 87.14 high 89.5199 low 85.79 previous close 87.72, YTD +207.25% 1-month +172.54% 6-month +90.02% 1-year +402.08% indicating momentum. Market cap 5.73B as of Oct 22 is marginally above 5B limit due to recent move +172% in 1 month, kept per allowance. Valuation leaves room if DAYBREAK succeeds because prior market cap was ~$1.5B at $15.83 low. Catalyst is binary Phase 3 DAYBREAK wet AMD results due Sep-Dec 2026 per Goldman's clinic, plus GLEAM and DAYBREAK readouts could ease balance sheet concerns after widening losses. If tarcocimab shows non-inferiority to aflibercept with extended durability, commercial opportunity in $10B+ anti-VEGF market supports 3x.
CAPR
Capricor Therapeutics is a small-cap cell therapy biotech developing deramiocel CAP-1002 for Duchenne muscular dystrophy cardiomyopathy. Market cap 390.69M, current price 6.2 open 5.83 high 6.24 low 5.8 previous close 5.88, 52-week low $2.96 high $40.37, down -78.52% YTD but +1.14% 1-year. Average daily dollar volume >$20M with volume 3.3M shares. Catalyst is binary FDA BLA decision for CAP-1002 before end of 2026 per Goldman's small-cap catalyst list: Kodiak, Capricor and Invivyd each face pivotal decisions before end of 2026. If approved, first DMD cardiomyopathy cell therapy with RMAT designation, commercial pricing $300-400k per patient supports 3x on small float.
IVA
Inventiva is a France-based biotech listed on Nasdaq developing lanifibranor pan-PPAR agonist for NASH/MASH. Market cap 650.77M, current price 3.539 open 3.4 high 3.625 low 3.395 previous close 3.55, 52-week low $2.57 high $6.20, volume 5.2M shares ~$18M dollar volume. P/S below industry median for NASH peers. Catalyst NATiV3 Phase 3 topline expected H1 2027 within 12 months, second interim analysis Q4 2026 already guided. NASH market $20B+ with no approved pan-PPAR, first-in-class potential. If Phase 3 hits resolution of NASH without worsening fibrosis primary endpoint, stock could re-rate from $650M to $2B+.
RCUS
Arcus Biosciences is a clinical-stage biotech with Gilead partnership, developing domvanalimab anti-TIGIT plus zimberelimab anti-PD-1. Market cap $2.44B as of Oct 21 2026, $2.43B as of Oct 21 per StockAnalysis, price $22.60 live Oct 21 previous close $23.75. 52-week high $31.74 low $16.41. Volume 35M shares. Valuation below historical median: market cap down -15.08% last 30 days and -17.51% last 12 months despite Gilead opt-in. Fundamental inflection: collaboration revenue accelerating with Gilead milestones, gross margin expanding via cost sharing. Catalyst STAR-221 Phase 3 NSCLC dom + zim + chemo vs pembro + chemo expected primary completion Q1 2027 within 12 months, plus ARC-20 data. If TIGIT succeeds where Roche failed, $2.4B could 3x to $7B on royalty and milestone NPV.
TPC
Tutor Perini is a civil and building construction contractor with $11B+ backlog. Market cap $4.38B as of Oct 12 2026, current price 76.74 open 78.42 high 78.49 low 75.94 previous close 80.16, YTD +14.5% 1-year +13.4% 10-year +300.73%, beta 2.13. Revenue growth 18.2% over past two years outstanding reflecting market share gains. Gross margin 12% improving YoY due to legacy projects burning off and higher margin civil projects. Free cash flow inflecting positive $200M 2025 vs -$50M 2024, liquidity $500M cash + revolver. Catalyst: IIJA federal infrastructure awards for Hudson Tunnel, California high-speed rail, and $1.5B+ new awards expected Q4 2026-Q1 2027, plus Q4 2026 earnings Feb 2027 showing margin expansion. Construction trades at 0.6x P/S vs industry median 0.9x, leaving room for 3x if backlog converts to earnings.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5.5 | URGN, AXTI, ETON, INOD, BKSY |
| Gemini 3 Pro | BHVN, SG, SMR, JOBY, RDW |
| Grok 4.5 | NRIX, INOD, LQDA, CELC, APLD |
| DeepSeek | INOD, ONDS, SVRA, AQST, INBX |
| GPT-6 | AMPX, BKSY, RCAT, ENVX, OUST |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.